{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:46:51Z","timestamp":1783784811606,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Recombinant human growth hormone (rhGH) treatment for short children born small for gestational age (SGA) is effective in improving height outcomes. Determinants of height response to rhGH treatment have been identified using multiple regression analyses. Although adverse events (AEs) associated with treatment have been described, determinants of AE occurrence are not well known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This analysis used safety data collected between 2007 and 2018 in an observational, prospective registry study (NCT01578135) including children born SGA across 126 sites in France. AEs were reported by patients or recorded by treating physicians. Univariate and multivariate analyses were performed to identify determinants of occurrence of AEs and serious AEs (SAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 291 patients from the registry, 287 AEs were reported in 149 (51.2%) patients. Each patient experienced a mean of 0.205 AEs per patient-year (range 0\u20134.3) and a mean of 0.054 SAEs (range 0\u20131.8). The most frequently reported AEs were headache (9.3%) and arthralgia (4.5%). Using multiple regression analyses, longer registry participation (p=0.0146, odds ratio [OR]=1.98), presence of chronic disease (p=0.0004, OR\u00a0=\u00a02.56), and concomitant treatment (p=0.0162, OR\u00a0=\u00a01.79) were associated with increased risk of experiencing AEs. GH dose at inclusion or cumulative GH dose during first 2 years of treatment were not associated with AE risk, while higher GH dose at last visit was associated with reduced risk (p=0.0412, OR\u00a0=\u00a00.58).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In short children born SGA, underlying conditions and associated treatments seem to be the main factors associated with AE occurrence, while GH dose was inversely related to AE occurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1656966","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:38:18Z","timestamp":1763534298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Determinants of adverse event occurrence in children with short stature born small for gestational age treated with growth hormone"],"prefix":"10.3389","volume":"16","author":[{"given":"Regis","family":"Coutant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazim","family":"Benchikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Nicolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1651-2227.1994.tb13292.x","article-title":"Natural growth in children born small for gestational age with and without catch-up growth","volume":"399","author":"Albertsson-Wikland","year":"1994","journal-title":"Acta Paediatr Suppl"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199508000-00022","article-title":"Children born small for gestational age: do they catch up","volume":"38","author":"Hokken-Koelega","year":"1995","journal-title":"Pediatr Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199511000-00017","article-title":"Growth in full-term small-for-gestational-age infants: from birth to final height","volume":"38","author":"Karlberg","year":"1995","journal-title":"Pediatr Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000053080","article-title":"Children born small-for-gestational age: postnatal growth and hormonal status","volume":"49","author":"Albertsson-Wikland","year":"1998","journal-title":"Horm Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnad002","article-title":"International Consensus Guideline on Small for Gestational Age (SGA): etiology and management from infancy to early adulthood","volume":"44","author":"Hokken-Koelega","year":"2023","journal-title":"Endocr Rev"},{"key":"B6","unstructured":"Opinion following an Article 7(5) referral norditropin International (Non-Proprietary Name: Somatropin)\n          \n          \n          \n          2003"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1203\/01.Pdr.0000148716.71231.81","article-title":"Final height in short children born small for gestational age treated with growth hormone","volume":"57","author":"Dahlgren","year":"2005","journal-title":"Pediatr Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.29.159","article-title":"The long-term safety and effectiveness of growth hormone treatment in Japanese children with short stature born small for gestational age","volume":"29","author":"Horikawa","year":"2020","journal-title":"Clin Pediatr Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1987","article-title":"Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial","volume":"97","author":"Lem","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-0293","article-title":"Impact of growth hormone therapy on adult height of children born small for gestational age","volume":"124","author":"Maiorana","year":"2009","journal-title":"Pediatrics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000508190","article-title":"Safety and effectiveness of omnitrope\u00ae, a biosimilar recombinant human growth hormone: more than 10 years' Experience from the PATRO children study","volume":"93","author":"Pf\u00e4ffle","year":"2020","journal-title":"Horm Res Paediatr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021172","article-title":"Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial","volume":"88","author":"Van Pareren","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000516557","article-title":"Determinants of final height in patients born small for gestational age treated with recombinant growth hormone","volume":"94","author":"Adler","year":"2021","journal-title":"Horm Res Paediatr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6421243","article-title":"Adult Height after Growth Hormone Treatment at Pubertal Onset in Short Adolescents Born Small for Gestational Age: Results from a Belgian Registry-Based Study","volume":"2018","author":"Thomas","year":"2018","journal-title":"Int J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1073","article-title":"Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (sga) and untreated short SGA controls","volume":"92","author":"van Dijk","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000530572","article-title":"Growth hormone dose modulation and final height in short children born small for gestational age: french real-life data","volume":"96","author":"Coutant","year":"2023","journal-title":"Horm Res Paediatr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ghir.2008.08.001","article-title":"Predicting growth in response to growth hormone treatment","volume":"19","author":"Ranke","year":"2009","journal-title":"Growth Horm IGF Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2008.03.003","article-title":"Optimal use of growth hormone therapy for maximizing adult height in children born small for gestational age","volume":"22","author":"Simon","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2046","article-title":"Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study","volume":"102","author":"Swerdlow","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(20)30163-7","article-title":"Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study","volume":"8","author":"S\u00e4vendahl","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad622","article-title":"Cerebrovascular abnormalities in adults born SGA at 12 years after growth hormone cessation compared to controls","volume":"109","author":"Dorrepaal","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"B23","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"15","year":"2004","journal-title":"J Int Bioethique"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practice (GPP)","volume":"25","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-195909000-00030","article-title":"Radiographic atlas of skeletal development of the hand and wrist","author":"Greulich","year":"1959","journal-title":"Stanford: Stanford Univ Press"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab080","article-title":"Long-term safety of growth hormone treatment in childhood: two large observational studies: NordiNet IOS and ANSWER","volume":"106","author":"S\u00e4vendahl","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e205199","DOI":"10.1001\/jamapediatrics.2020.5199","article-title":"Association of childhood growth hormone treatment with long-term cardiovascular morbidity","volume":"175","author":"Tidblad","year":"2021","journal-title":"JAMA Pediatr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2014.57.9.379","article-title":"Efficacy and safety of growth hormone treatment for children born small for gestational age","volume":"57","author":"Hwang","year":"2014","journal-title":"Korean J Pediatr"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.10.6917","article-title":"Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency","volume":"85","author":"Sas","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(17)30311-x","article-title":"Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study","volume":"5","author":"van der Steen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.1.8293","article-title":"High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity","volume":"87","author":"de Zegher","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14603","article-title":"Greater insulin resistance in short children born small-for-gestational age than in children with growth hormone deficiency at the early period of growth hormone therapy","volume":"63","author":"Suzuki","year":"2021","journal-title":"Pediatr Int"},{"key":"B33","article-title":"Small for gestational age (SGA): endocrine and metabolic consequences and effects of growth hormone treatment","volume":"17","author":"Hokken-Koelega","year":"2004","journal-title":"J Pediatr Endocrinol Metab"}],"updated-by":[{"DOI":"10.3389\/fendo.2025.1754016","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1656966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T14:09:15Z","timestamp":1765202955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1656966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":33,"alternative-id":["10.3389\/fendo.2025.1656966"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1656966","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1656966"}}